E0 ConsensusPreliminaryPEM not requiredSystematic-ReviewPeer-reviewedReviewed
Standard · 3 min
Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review.
Gindri, Izabelle de Mello, Ferrari, Gustavo, Pinto, Luiz Paulo S et al. · American journal of physiology. Endocrinology and metabolism · 2024 · DOI
Quick Summary
This review examined whether taking NAD+ or NADH supplements (molecules that help cells produce energy) are safe and helpful for people with different health conditions, including chronic fatigue syndrome. Researchers looked at 10 clinical trials involving 489 people and found that these supplements were generally well-tolerated, with some people reporting improvements in fatigue, quality of life, and sleep. The most common side effects were mild and included muscle pain, headaches, and sleep disturbances, but nothing serious.
Why It Matters
For ME/CFS patients, this review is important because it specifically examined NAD/NADH supplementation in people with CFS and reported improvements in fatigue intensity and quality of life—two core symptoms that significantly impact daily functioning. The finding that these supplements are generally safe with minimal serious side effects may inform patient and clinician discussions about potential therapeutic options, though more targeted research is still needed.
Observed Findings
NADH supplementation was associated with improvements in fatigue intensity, quality of life, and sleep quality in CFS patients.
Common side effects included muscle pain, nervous disorders, fatigue, sleep disturbance, and headaches, though none were classified as serious health risks.
NADH supplementation led to decreased anxiety, reduced maximum heart rate after stress testing, and improved insulin sensitivity and signaling.
Inflammatory markers (serum and cerebrospinal fluid cytokines) showed reduction with NAD/NADH treatment.
All studies reported some adverse events, but the incidence was low and no serious safety concerns emerged.
Inferred Conclusions
Oral NADH supplementation is safe and well-tolerated with low incidence of adverse effects across tested populations.
NADH may improve general quality of life and several health parameters including fatigue, anxiety, and metabolic markers.
The mild side effect profile supports continued investigation of NAD/NADH as a potential therapeutic intervention.
Future research with standardized dosing and outcome measures is needed to clarify disease-specific benefits.
Remaining Questions
What are the optimal doses and treatment durations of NAD/NADH for ME/CFS specifically?
What This Study Does Not Prove
This review does not prove that NAD/NADH supplements are definitively effective for ME/CFS specifically, as the included studies evaluated diverse conditions with varied outcome measures and dosing protocols. It also does not establish optimal dosing, duration of treatment, or which ME/CFS patient subgroups might benefit most. The studies reviewed were heterogeneous, making it difficult to draw disease-specific conclusions.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
Which ME/CFS patient phenotypes or biomarker profiles are most likely to respond to NAD/NADH supplementation?
How do NAD/NADH effects on mitochondrial function and ATP production directly correlate with symptom improvement in ME/CFS?
Why do some studies show benefit while others do not, and can this variation be explained by differences in patient selection, dosing, or outcome measurement?